SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’, announced today that its board of directors has appointed Philip Chamberlain, D.Phil. as Chief Executive Officer.
Chamberlain has extensive biotechnology leadership experience and most recently served as Executive Director at Celgene where he built and led its structural and chemical biology department. Chamberlain was responsible for several fundamental scientific breakthroughs on the mechanism of action of thalidomide analogs as prototype molecular glues, including the structural basis for cereblon binding and neosubstrate recruitment, the definition of the neosubstrate structural degron, and a molecular explanation for the thalidomide teratogenicity tragedy. Based on these discoveries, he led the construction of the cereblon modulator platform at Celgene, the pioneering drug discovery effort in the molecular glue field. Chamberlain has published work on targeted protein degradation in journals including Nature, Nature Structural and Molecular Biology and Nature Chemical Biology.
“Phil was integral to the founding of Neomorph and is passionate about pushing the boundaries of new modalities to enable the discovery of advanced new therapeutics,” said Cam Wheeler, Ph.D., Deerfield Management Partner. “We are excited to welcome him as Chief Executive Officer and look forward to benefiting from his expertise and leadership as Neomorph continues its growth strategy.”
“I am honored to take on the role of CEO as we advance on our mission to discover transformational therapeutics,” said Chamberlain. “I have been working in the degrader field for more than a decade, and co-founding Neomorph has provided an opportunity to build a specialist molecular glue company from the ground up. We have assembled a wonderful team of employees, founders, and investors, all of whom share the deepest commitment to the field. I am extremely excited to see what we will be able to achieve.”
“Neomorph will be well served under Phil’s capable leadership,” said Eric Fischer, co-founder of Neomorph and Independent Investigator at the Dana-Farber Cancer Institute. “Phil has an outstanding career in biotechnology and his scientific expertise and leadership make him ideally qualified to lead the company through its next chapter. I am delighted to continue working closely with Phil in pushing the boundaries of this exciting therapeutic area.”
About Neomorph
Neomorph is a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against undruggable targets.
Neomorph’s team is comprised of industry leading experts in protein degradation and molecular glues who have a track record of ground-breaking discoveries in the field. The team at Neomorph is committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development.
Neomorph is headquartered in San Diego, California, and has a key collaboration with the Center for Protein Degradation at the Dana-Farber Cancer Institute.
